News

The Nasdaq climbed to a fresh high Monday as tech stocks gained ahead of an expected decision on interest rates from the Federal Reserve later this week.

On Monday, Larimar Therapeutics, Inc. (NASDAQ:LRMR) released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s Ataxia. Friedreich’s Ataxia is caused by a mutation in the FXN gene, which carries the code for the frataxin protein. Frataxin is important for the normal function of mitochondria, the energy-producing parts of cells At the time of data cut

IPO Edge hosted a fireside chat on Dec. 10 at Nasdaq MarketSite with J.D. Moriarty, Chief Executive Officer of ICR Capital. The in-person interview was joined by Editor-in-Chief John Jannarone and they […]

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic transmission.

Oppenheimer boosted Netflix's price target, pointing to the benefits of the biggest streaming service's live events.

Here’s what could be next for the AI network provider.

Affirm Holdings (AFRM) is in a position to expand its total addressable market, leveraging its buy-n